SWTX SEC Form 4 filings

Springworks Therapeutics, Inc. Latest Insider Trading Activity

Our insider trading activity tracker for Springworks Therapeutics, Inc. shows 21 total open-market insider transactions for SWTX over the past 1,801 days. The latest displayed record by transaction date reports 4 sales by Edris Badreddin (Springworks Therapeutics, Inc. Chief Operating Officer) totaling 20,000 shares at a weighted-average price of $54.23 per share, with the latest transaction dated March 3, 2025. This page shows up to the 10 most recent SEC Form 4 filing records on a 6-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.

Insider Trading For SWTX Charted on Daily Candles. Scroll left or zoom out to load earlier candles (up to 2 years).

▲ Insider buy ▼ Insider sale
Loading daily price history…
Charting by TradingView Lightweight Charts
Ticker Filing Date Transaction Date Company Insider Title Transaction Trade Count Shares Avg. Price Total Value Position Size Change SEC Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-03-05 2025-03-03 Springworks Therapeutics, Inc. Edris Badreddin Chief Operating Officer Sell 4 20,000 $54.23 $1,084,596.92 2.78% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-03-05 2025-03-03 Springworks Therapeutics, Inc. Islam Saqib Chief Executive Officer Sell 5 49,000 $54.24 $2,657,566.00 1.00% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-02-24 2025-02-20 Springworks Therapeutics, Inc. Islam Saqib Chief Executive Officer Sell 2 29,328 $60.30 $1,768,390.32 1.39% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-02-24 2025-02-20 Springworks Therapeutics, Inc. Ashar Bhavesh Chief Commercial Officer Sell 1 1,016 $61.19 $62,169.04 1.61% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-02-24 2025-02-20 Springworks Therapeutics, Inc. Lynch Daniel Director Sell 2 47,600 $60.22 $2,866,604.20 21.93% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-02-19 2025-02-14 Springworks Therapeutics, Inc. Islam Saqib Chief Executive Officer Sell 1 10,672 $59.92 $639,466.24 0.99% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-02-12 2025-02-10 Springworks Therapeutics, Inc. Pichl Daniel Chief People Officer Sell 3 29,750 $54.36 $1,617,325.00 14.51% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2025-02-12 2025-02-10 Springworks Therapeutics, Inc. Hambleton Julie Director Sell 1 13,774 $53.01 $730,159.74 77.08% View Filing
10b5-1: Scheduled Form 4 Transaction SWTX 2024-02-20 2024-02-16 Springworks Therapeutics, Inc. Pichl Daniel Chief People Officer Sell 1 15,000 $50.10 $751,500.00 24.91% View Filing
Explained M/S: sale activity tied to share conversions or derivative-related share movements. SWTX 2021-10-13 2021-10-13 Springworks Therapeutics, Inc. Smith L. Mary Chief Development Officer Sell 1 10,000 $55.97 $559,700.00 5.63% View Filing

Pricing

Free Trial

10 trading days
$0

Explore every Premium feature before you pay.

  • Full platform access
  • 10 trading days
  • No credit card required
  • 20 years of alert history
  • Live alert directory updates
Start your free trial

Standard Monthly

Scheduled
$19.99 / month

Scheduled alerts with complete trade context.

  • Email and Telegram delivery
  • Alert intervals from every sixty minutes to once daily
  • Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
  • Highlighted cluster transactions and SEC filing links
  • Access to the alert directory hourly refreshes
Choose Standard Monthly

Premium Monthly

Recommended
$29.99 / month

Fastest alerts with ticker-level control.

  • Everything in Standard
  • Instant delivery detection-to-outbound time averages 3.00 seconds
  • Alert intervals starting from one minute
  • Real time alert directory updates
Choose Premium Monthly
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.